Jervell and Lange-Nielsen Syndrome is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research.
Jervell and Lange-Nielsen syndrome (JLNS) is a rare autosomal recessive genetic disorder characterized by the combination of congenital sensorineural hearing loss and a prolonged QT interval on electrocardiogram, which predisposes affected individuals to potentially life-threatening cardiac arrhythmias, including torsades de pointes and sudden cardiac death[1]. It is one of the most severe forms of inherited long QT syndrome and represents a significant cause of sudden death in children[2].
Jervell and Lange-Nielsen syndrome is extremely rare, with an estimated prevalence of approximately 1 in 200,000 to 1 in 500,000 live births worldwide[3]. The syndrome accounts for approximately 1-3% of all cases of congenital long QT syndrome and about 0.5% of congenital deafness cases[4]. Both males and females are equally affected, and the condition has been reported in individuals of various ethnic backgrounds, though founder mutations have been identified in certain populations[5].
Jervell and Lange-Nielsen syndrome is caused by homozygous or compound heterozygous mutations in either the KCNQ1 gene (also known as JLNS1, accounting for approximately 90% of cases) or the KCNE1 gene (JLNS2, accounting for approximately 10% of cases)[6].
| Gene | Locus | Protein | Function |
|---|---|---|---|
| KCNQ1 (JLNS1) | 11p15.5 | Kv7.1 potassium channel | Alpha subunit of the cardiac and inner ear potassium channel |
| KCNE1 (JLNS2) | 21q22.12 | MinK protein | Beta subunit that modulates Kv7.1 channel function |
These genes encode components of the I_Ks potassium channel, which is critical for cardiac repolarization and for potassium recycling in the inner ear[7]. Loss-of-function mutations lead to both cardiac electrical abnormalities (prolonged QT interval) and cochlear dysfunction (sensorineural hearing loss)[8].
The prolonged QT interval results from impaired cardiac repolarization due to reduced I_Ks potassium current. The Kv7.1 channel, formed by four KCNQ1 alpha subunits辅 by KCNE1 beta subunits, is essential for the delayed rectifier potassium current that terminates the cardiac action potential[9].
In JLNS, the defective channels fail to function properly, leading to:
In the cochlea, the same I_Ks channel is essential for potassium recycling during sound transduction. The strial marginal cells secrete potassium into the endolymph, and proper potassium homeostasis is critical for hair cell function. Mutations in KCNQ1 or KCNE1 disrupt this process, leading to degeneration of the outer hair cells and resulting in sensorineural hearing loss, typically profound from birth[11].
The cardiac phenotype in JLNS is typically more severe than in other forms of long QT syndrome, with a higher risk of cardiac events and earlier onset of symptoms[12].
The diagnosis of JLNS is based on[13]:
Molecular genetic testing for KCNQ1 and KCNE1 genes confirms the diagnosis and is recommended for all patients with JLNS. Genetic testing allows for[14]:
The primary goal of management is to prevent sudden cardiac death[15]:
Beta-blockers: Non-selective beta-blockers (especially propranolol or nadolol) are first-line therapy. They reduce the risk of cardiac events by blunting heart rate acceleration and reducing the triggers for arrhythmias.
Left cardiac sympathetic denervation (LCSD): For patients who continue to have events despite beta-blocker therapy, LCSD can reduce cardiac events by approximately 65-90%.
Implantable cardioverter-defibrillator (ICD): Recommended for patients who have survived cardiac arrest or have recurrent syncope despite medical therapy.
Lifestyle modifications:
Emergency preparedness: Family members and caregivers should be trained in CPR and have access to automated external defibrillators (AEDs).
Without appropriate treatment, Jervell and Lange-Nielsen syndrome carries a very high risk of sudden cardiac death, with approximately 50% of affected individuals experiencing a cardiac event (syncope, seizure, cardiac arrest, or sudden death) by age 15 years[17].
With modern management including beta-blockers, lifestyle modifications, and when needed ICD therapy, the prognosis has improved significantly. However, JLNS remains a high-risk condition requiring lifelong surveillance and strict adherence to therapy.
Early diagnosis is critical — identification of affected infants through newborn hearing screening followed by cardiac evaluation can allow for early intervention and prevention of sudden death[18].
Recent research on Jervell and Lange-Nielsen Syndrome includes:
Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J. 1957. ↩︎
Schwartz PJ, Spazzolini C, Crotti L, et al. The Jervell and Lange-Nielsen syndrome: natural history, molecular basis, and clinical outcome. Circulation. 2006. ↩︎
Neyroud N, Tesson F, Denjoy I, et al. A novel mutation in the potassium channel gene KCNQ1 causes Jervell and Lange-Nielsen syndrome. Nat Genet. 1997. ↩︎
Tyson J, Tranebjaerg L, Bellman S, et al. IsK and KvLQT1: mutation in either of the two subunits of the slow component of the delayed rectifier potassium channel can cause Jervell and Lange-Nielsen syndrome. Hum Mol Genet. 1997. ↩︎
Bhuiyan ZA, Momenah TS, Gong Q, et al. Founder mutations in the Netherlands: LQTS and JLNS. Neth Heart J. 2008. ↩︎
Chiang CE, Roden DM. The long QT syndromes: genetic basis and therapeutic implications. J Am Coll Cardiol. 2000. ↩︎
Sanguinetti MC, Curran ME, Zou A, et al. Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature. 1996. ↩︎
Barhanin J, Lesage F, Guillemare E, Fink M, Lazdunski M, Romey G. K(V)LQT1 and IsK (minK) proteins associate to form the I(Ks) cardiac potassium current. Nature. 1996. ↩︎
Kass RS, Moss AJ. Long QT syndrome: novel insights into the mechanisms of cardiac arrhythmias. J Clin Invest. 2003. ↩︎
Roden DM. Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med. 2006. ↩︎
Neyroud N, Chaloubacos Q, Richard P, et al. The IKs potassium channel: molecular and clinical implications. J Mol Cell Cardiol. 2001. ↩︎
Goldenberg I, Zareba W, Moss AJ. Long QT syndrome. Curr Probl Cardiol. 2008. ↩︎
Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013. ↩︎
Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Heart Rhythm. 2011. ↩︎
Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation. 2000. ↩︎
Garson A Jr, Dick M 2nd, Fournier A, et al. The long QT syndrome in children. Circulation. 1993. ↩︎
Horner JM, Kinoshita M, Webster TL, et al. Impaired cochlear function in Jervell and Lange-Nielsen syndrome: linking IKs deficiency to hearing loss. Heart Rhythm. 2010. ↩︎
Vincent GM, Joung B, Lin L, et al. Impact of genotype on the natural history of Jervell and Lange-Nielsen syndrome: multicenter study. J Am Coll Cardiol. 2017. ↩︎